READ-ONLY DIGITIZATION RESULT
Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study.
J Clin Oncol · 2025-Aug-20 · PMID 40623279
Panel F提取完成待 EXE 对齐验证
overall survival
FIG 2. Kaplan-Meier curves in the ITT set of EFS per IRC (A), PFS per IRC (B), DOR per IRC (C), duration of CR per IRC (D), OS based on the ITT principle (E), and OS based on two-stage accelerated failure time model (F). CR, complete response; DOR, duration of response; EFS, event-free survival; HR, hazard ratio; IRC, independent review committee; ITT, intention-to-treat; liso-cel, lisocabtagene maraleucel; NR, not reached; OS, overall survival; PFS, progression-free survival; SOC, standard of care.
算法:legacy-0.5.0引擎:enhanced-linux
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | complete | 待验证 | 2 | 2026-07-23T17:33:29+00:00 |